SMARCB1 and rhabdoid tumor: Loss of SMARCB1 in rhabdoid tumors has been associated with deregulation of the cyclin D-CDK4/6-RB axis [30–32], and CDK4/6 inhibitors were among the inhibitors with the most promising activity profile in ATRT cells.